Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Suggests Pristiq Could Surpass Effexor XR In Depression Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Combined global market for major depressive disorder and vasomotor symptoms represents 35 million women, firm says during Goldman Sachs investor conference.

You may also be interested in...



FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim

Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.

FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim

Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.

Noven Gains Phase III Vasomotor Symptoms Candidate With JDS Acquisition

Miami firm predicts four potential new product launches in four years based on specialty pharma JDS’ pipeline.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel